PE20231097A1 - Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso - Google Patents
Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de usoInfo
- Publication number
- PE20231097A1 PE20231097A1 PE2022000849A PE2022000849A PE20231097A1 PE 20231097 A1 PE20231097 A1 PE 20231097A1 PE 2022000849 A PE2022000849 A PE 2022000849A PE 2022000849 A PE2022000849 A PE 2022000849A PE 20231097 A1 PE20231097 A1 PE 20231097A1
- Authority
- PE
- Peru
- Prior art keywords
- delta
- 4alkoxy
- methods
- heterocyclic compounds
- haloc1
- Prior art date
Links
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 title abstract 3
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- FVZCHYQRJNSUIK-UHFFFAOYSA-N FC(CN1N=CC(=C1)C1=C(N=C2N(C1=O)C=CS2)C(F)(F)F)(C(F)(F)F)F Chemical compound FC(CN1N=CC(=C1)C1=C(N=C2N(C1=O)C=CS2)C(F)(F)F)(C(F)(F)F)F FVZCHYQRJNSUIK-UHFFFAOYSA-N 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Refiere a compuestos utiles para la inhibicion de Delta-5 Desaturasa ("D5D"), en donde el grupo x, y, z, junto con el atomo de N y C al que se unen, forma un anillo aromatico, insaturado, saturado o parcialmente saturado, y se selecciona de CR, CRR', N, NR'', O, S(O)n, C=O, C=S y C=NH, en donde R, R' y R'' se seleccionan de -(CH2)m(cicloalquilo C3-5), - CH2(heterocicloalquilo C3-5), entre otros; R1 es O, S o NH; R2 se sustituye opcionalmente con uno o dos sustituyentes R3', como alcoxilo C1-4, haloalcoxilo C1-4, entre otros, asimismo, el anillo A es un heteroarilo de 5 miembros seleccionados de N, S y O y R3 se selecciona de -NHCH2(cicloalquilo C3-5), -S(O)nCH2(cicloalquilo C3-5), entre otros; R4 es haloalcoxilo C1-4, cicloalquilo C3-5, ciclohaloalquilo C3-5, entre otros; m es 0,1 o 2 y n es 1 o 2. Dicho compuesto se selecciona del grupo de, 6-[1-(2,2,3,3,3-pentafluoropropil)-1H-pirazol-4-il]-7-(trifluorometil)-5H-[1,3]tiazolo[3,2-a]pirimidin-5-ona entre otros. Ademas, en la presente se menciona una composicion farmaceutica que comprende el compuesto y un excipiente farmaceuticamente aceptable para su uso como medicamento para el tratamiento de la diabetes, obesidad, dislipidemia o esteatohepatitis no alcoholica (NASH).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939821P | 2019-11-25 | 2019-11-25 | |
| PCT/US2020/062020 WO2021108408A1 (en) | 2019-11-25 | 2020-11-24 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231097A1 true PE20231097A1 (es) | 2023-07-18 |
Family
ID=73855555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000849A PE20231097A1 (es) | 2019-11-25 | 2020-11-24 | Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11512097B2 (es) |
| EP (1) | EP4065223A1 (es) |
| JP (2) | JP7254246B2 (es) |
| KR (2) | KR102598203B1 (es) |
| CN (1) | CN114728167B (es) |
| AR (1) | AR120556A1 (es) |
| AU (1) | AU2020392087A1 (es) |
| BR (1) | BR112022010054A2 (es) |
| CA (1) | CA3162281A1 (es) |
| CL (2) | CL2022001357A1 (es) |
| CO (1) | CO2022008690A2 (es) |
| CR (1) | CR20220308A (es) |
| IL (1) | IL293191A (es) |
| JO (1) | JOP20220125A1 (es) |
| MX (1) | MX2022006281A (es) |
| PE (1) | PE20231097A1 (es) |
| TW (1) | TWI815061B (es) |
| UY (1) | UY38971A (es) |
| WO (1) | WO2021108408A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021108408A1 (en) | 2019-11-25 | 2021-06-03 | Amgen Inc. | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
| CN115557903A (zh) * | 2022-09-27 | 2023-01-03 | 山东潍坊润丰化工股份有限公司 | 一种特草定的制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3130633A1 (de) | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
| EP0242690B1 (en) | 1986-04-07 | 1993-06-30 | Kumiai Chemical Industry Co., Ltd. | 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same |
| IL130181A0 (en) | 1996-12-05 | 2000-06-01 | Amgen Inc | Substituted pyrimidone and pyridone compounds and methods of use |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6537998B1 (en) * | 1999-10-15 | 2003-03-25 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| MXPA02003614A (es) | 1999-10-15 | 2002-10-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos.. |
| WO2003106435A1 (en) | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| JP2004107228A (ja) | 2002-09-17 | 2004-04-08 | Nippon Nohyaku Co Ltd | 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤 |
| PE20051089A1 (es) | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| WO2007002701A2 (en) | 2005-06-27 | 2007-01-04 | Amgen Inc. | Anti-inflammatory aryl nitrile compounds |
| WO2007027012A1 (en) | 2005-07-18 | 2007-03-08 | Samsung Electronics Co., Ltd. | Video coding method and apparatus for reducing mismatch between encoder and decoder |
| EP1915376B1 (de) | 2005-07-27 | 2009-09-09 | Basf Se | Fungizide 6-phenyl-pyrazolopyrimidin-7-ylamine |
| JP2009502865A (ja) | 2005-07-27 | 2009-01-29 | ビーエーエスエフ ソシエタス・ヨーロピア | 殺菌剤６−フェニルトリアゾロピリミジニルアミン |
| EP1909580A1 (de) | 2005-07-27 | 2008-04-16 | Basf Se | Fungizide 5-methyl-6-phenyl-triazolopyrimidinylamine |
| CN101360499B (zh) | 2005-10-06 | 2015-10-07 | 默沙东公司 | 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途 |
| EP2074127A1 (en) | 2006-09-28 | 2009-07-01 | Novartis AG | Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use |
| WO2008057601A2 (en) | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| BRPI0806347A2 (pt) | 2007-01-19 | 2011-09-06 | Basf Se | misturas fungicidas, agente fungicida, método para combater fungos nocivos fitopagênicos, semente, e, processo para preparar um agente |
| WO2008092836A2 (en) | 2007-01-30 | 2008-08-07 | Basf Se | Method for improving plant health |
| WO2008116730A1 (de) | 2007-03-23 | 2008-10-02 | Basf Se | Wirkstoffkombinationen |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20090253704A1 (en) * | 2008-04-04 | 2009-10-08 | Dmitry Koltun | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US8119647B2 (en) * | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| WO2010087467A1 (en) | 2009-01-27 | 2010-08-05 | Takeda Pharmaceutical Company Limited | Delta-5-desaturase inhibitors |
| AU2010273816B2 (en) | 2009-06-29 | 2015-07-09 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
| WO2011114148A1 (en) * | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| WO2012011592A1 (ja) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US8952012B2 (en) | 2012-05-24 | 2015-02-10 | Colorado State University Research Foundation | Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease |
| WO2014139326A1 (en) | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| US9505767B2 (en) | 2013-09-05 | 2016-11-29 | Genentech, Inc. | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors |
| WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| WO2015135094A1 (en) | 2014-03-13 | 2015-09-17 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| BR112016024455B1 (pt) | 2014-04-23 | 2023-02-07 | Mitsubishi Tanabe Pharma Corporation | Composto heterocíclico bicíclico ou tricíclico |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| JP6791717B2 (ja) | 2015-10-22 | 2020-11-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2017112678A1 (en) | 2015-12-21 | 2017-06-29 | Rima Mcleod | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| CN109890822B (zh) | 2016-08-31 | 2022-08-30 | 安吉奥斯医药品有限公司 | 细胞代谢过程的抑制剂 |
| CN106749271B (zh) | 2016-12-07 | 2019-04-05 | 青岛科技大学 | 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| WO2018229683A1 (en) | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| US10738056B2 (en) | 2017-09-15 | 2020-08-11 | Aduro Biotech Inc. | Pyrazolopyrimidinone compounds and uses thereof |
| WO2021108408A1 (en) | 2019-11-25 | 2021-06-03 | Amgen Inc. | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
-
2020
- 2020-11-24 WO PCT/US2020/062020 patent/WO2021108408A1/en active Application Filing
- 2020-11-24 CN CN202080081465.8A patent/CN114728167B/zh active Active
- 2020-11-24 BR BR112022010054A patent/BR112022010054A2/pt unknown
- 2020-11-24 AU AU2020392087A patent/AU2020392087A1/en active Pending
- 2020-11-24 JO JOP/2022/0125A patent/JOP20220125A1/ar unknown
- 2020-11-24 JP JP2022529556A patent/JP7254246B2/ja active Active
- 2020-11-24 CA CA3162281A patent/CA3162281A1/en active Pending
- 2020-11-24 US US17/103,389 patent/US11512097B2/en active Active
- 2020-11-24 CR CR20220308A patent/CR20220308A/es unknown
- 2020-11-24 KR KR1020227021152A patent/KR102598203B1/ko active IP Right Grant
- 2020-11-24 KR KR1020237037455A patent/KR20230154292A/ko not_active Application Discontinuation
- 2020-11-24 EP EP20828193.1A patent/EP4065223A1/en active Pending
- 2020-11-24 PE PE2022000849A patent/PE20231097A1/es unknown
- 2020-11-24 IL IL293191A patent/IL293191A/en unknown
- 2020-11-24 MX MX2022006281A patent/MX2022006281A/es unknown
- 2020-11-25 TW TW109141315A patent/TWI815061B/zh active
- 2020-11-25 AR ARP200103274A patent/AR120556A1/es unknown
- 2020-11-25 UY UY0001038971A patent/UY38971A/es unknown
-
2021
- 2021-03-16 US US17/203,457 patent/US20210221824A1/en not_active Abandoned
-
2022
- 2022-05-24 CL CL2022001357A patent/CL2022001357A1/es unknown
- 2022-06-22 CO CONC2022/0008690A patent/CO2022008690A2/es unknown
- 2022-11-18 US US18/056,863 patent/US20230159560A1/en active Pending
-
2023
- 2023-03-27 JP JP2023049452A patent/JP2023078418A/ja active Pending
- 2023-08-22 CL CL2023002486A patent/CL2023002486A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI815061B (zh) | 2023-09-11 |
| KR20230154292A (ko) | 2023-11-07 |
| BR112022010054A2 (pt) | 2022-08-16 |
| US20210188874A1 (en) | 2021-06-24 |
| CA3162281A1 (en) | 2021-06-03 |
| CR20220308A (es) | 2022-08-04 |
| JOP20220125A1 (ar) | 2023-01-30 |
| EP4065223A1 (en) | 2022-10-05 |
| CO2022008690A2 (es) | 2022-06-30 |
| US20230159560A1 (en) | 2023-05-25 |
| KR20220106159A (ko) | 2022-07-28 |
| JP2022549739A (ja) | 2022-11-28 |
| CL2023002486A1 (es) | 2024-01-12 |
| CN114728167A (zh) | 2022-07-08 |
| JP2023078418A (ja) | 2023-06-06 |
| JP7254246B2 (ja) | 2023-04-07 |
| UY38971A (es) | 2021-06-30 |
| CN114728167B (zh) | 2024-03-19 |
| US11512097B2 (en) | 2022-11-29 |
| IL293191A (en) | 2022-07-01 |
| CL2022001357A1 (es) | 2023-03-10 |
| AR120556A1 (es) | 2022-02-23 |
| US20210221824A1 (en) | 2021-07-22 |
| TW202132317A (zh) | 2021-09-01 |
| AU2020392087A1 (en) | 2022-06-09 |
| MX2022006281A (es) | 2022-06-08 |
| KR102598203B1 (ko) | 2023-11-03 |
| WO2021108408A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001357A2 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| SE0402735D0 (sv) | Novel compounds | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| EA201990518A1 (ru) | Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1 | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| EA201891463A1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK) | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| PE20231097A1 (es) | Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| UY30183A1 (es) | Derivados de quinolina | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| CL2008003786A1 (es) | Compuestos derivados de 1h-pirazolo[3,4-c]piridazinilo, 1h pirazolo[3,4-b]piridinilo, ah-pirazolo[3,4-c]piridinilo e indazolilo, inhibidores no nucleosidicos de la transcriptasa reversa del vih-1(nnrti); composicion fa<rma<ceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por viv, sida o arc. | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| RU2017117559A (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение | |
| PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| PE20212331A1 (es) | Derivados de pirrolotriazina para tratar enfermedades mediadas por kit y pdgfra | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| PE20191006A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos | |
| PE20201068A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos | |
| BR112023025599A2 (pt) | Ativadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| PH12020500660A1 (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 `,2`:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| EA202190064A1 (ru) | Цианотриазоловые соединения и варианты их применения |